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Abstract 
Background: Neuroblastomas account for 97% of all neuroblastic tumors and for 
approximately 15% of all pediatric cancer fatalities. However, in adults neuroblastoma is 
a very rare finding.  
Case Report: Here, we present the case of a 55-year-old patient who was diagnosed with 
neuroblastoma stage IV one year after the false diagnosis of a non-secretory multiple 
myeloma.  
Results: The patient received six cycles of a chemotherapy protocol with cisplatin, 
etoposide and vindesine alternating with vincristine, dacarbazine, ifosfamide and 
doxorubicin, but the response to treatment was insufficient (stable disease).  
Conclusion: The standard chemotherapy protocols used for children are not sufficient for 
adult patients. Different treatment approaches are needed to improve the prognosis of 
adult patients with neuroblastoma. 
 
Introduction 
Neuroblastic tumors derive from neuroectodermal cells of the peripheral neural crest 
that are destined for the adrenal medulla and sympathetic nervous system. After birth, the 
extramedullary para-aortic paraganglia gradually atrophy and normally disappear by the 
age of two to three years. The malignant transformation of residual microscopic 
neuroblastic nodules may result from a failure of these cells to respond adequately to the 
normal signals that stimulate differentiation or apoptosis.  
Neuroblastoma is almost exclusively a disease of children. Approximately 40% are 
diagnosed before one year of age; the average age at diagnosis is about 17 months. Only 
2% of cases are found in patients over the age of 10 years [1]. The diagnosis of 
neuroblastoma in adults has been reported in several case reports [2–4]. Notably, most of  
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the described patients were young adults with a median age below 35 years at diagnosis. 
Here, we report the case of a 55-year-old patient diagnosed with neuroblastoma stage IV. 
Case Report 
A 55-year-old man was diagnosed with a poorly differentiated non-secretory multiple myeloma in 
January 2009 by biopsy from a mediastinal tumor in a peripheral hospital. CT scan showed osteolytic 
lesions in the thoracic vertebral bodies 6–10. Apart from hypertension, there was no further recorded 
medical history. In January and March 2009, the patient received radiation therapy of the thoracic 
vertebral bodies 6–10 with a total of 60 gray. In March 2010, chemotherapy with bortezomib and 
dexamethasone was initiated because of advancing osteolytic lesions. In April 2010, the patient was 
referred to our hospital with an increasing pain in the pelvis and the os sacrum. 
Physical examination revealed a palpable solid supraclavicular tumor of 2 × 3 cm in size. In the 
laboratory tests, a hemoglobin level of 9.5 g/dl, a platelet count of 11 × 10
9/l and a white blood cell count 
of 3.3 × 10
9 cells/l with 75% polymorphonuclear leukocytes and 15% lymphocytes were observed. The 
LDH (540 U/l; normal < 250 U/l), the CRP (4.7 mg/dl; normal < 0.5 mg/dl) and the serum neuron-
specific enolase (335 ng/ml; normal < 16.3 ng/ml) were elevated. The excretion of dopamine (1,197 
μg/24 h; normal < 500 mg/24 h), metanephrine (1.39 mg/24 h; normal < 1.2 mg/24 h), mandelic acid 
(44.8 mg/24 h; normal < 6.8 mg/24 h) and homovanillic acid (75.8 mg/24 h; normal < 8 mg/24 h) was 
increased, whereas the excretion of adrenaline was normal.  
Immunophenotyping of the peripheral blood showed an inverse CD4/CD8 T cell ratio, but no 
plasma cells or leukemic lymphoma cells. The bone marrow biopsy displayed dysplastic erythroid and 
megakaryocytic changes with no sign of the previously diagnosed multiple myeloma. However, blast 
cells were found in the bone marrow smear (fig. 1a). Immunohistological examination revealed a blastic 
neoplasm with profound marrow infiltration, fibrosis and displacement of the hematopoiesis, strongly 
expressing the neuronal markers neuron-specific enolase (fig. 1b), chromogranin and CD56, thus 
suggesting the diagnosis of a neuroblastoma. The plasma cell marker VS38c was positive; however, 
CD138 was negative. Fluorescence in situ hybridization revealed a hyperploid karyotype. NMYC 
amplification and 1p-deletion were not detectable. Histological examination of the surgically removed 
tumorous supraclavicular lymph node showed a stroma-poor neuroblastoma with low differentiation 
and a low mitosis-karyorrhexis index, grade 2, according to the Hughes classification. 
The subsequent staging examinations (PET-CT scan of the cranium, neck, chest and abdomen; fig. 
2a; MRT scan of the cranium and the thoracic and lumbar spine;  metaiodobenzylguanidine (MIBG) 
scintigraphy; fig. 2b) revealed a stage IV disease with disseminated manifestations (meningeal, 
supraclavicular, paravertebral and osseous tumors as well as a diffuse bone marrow infiltration). 
Treatment with cisplatin, etoposide and vindesine alternating with vincristine, dacarbazine, 
ifosfamide and doxorubicin analogous to the German NB-2004-HR study, which is designed for the 
treatment of children (Neuroblastoma Study Centre, Pediatric Clinic, University of Cologne, Cologne, 
Germany), was initiated after completion of the staging examinations. Chemotherapy was started with 
75% of the intended dose and was escalated to 100% since the patient tolerated the treatment very well. 
The response to treatment, however, was insufficient. After six cycles of chemotherapy, the neuron-
specific enolase decreased to 45.8 ng/ml, but there was less change in the excretion of dopamine (896 
μg/24 h), mandelic acid (14.6 mg/24 h) and homovanillic acid (33.9 mg/24 h). The tumorous lesions 
were unchanged, as determined by PET-CT and the bone marrow biopsy displayed persistent 
neuroblastoma infiltration. The treatment will be continued including high-dose chemotherapy 
followed by autologous peripheral blood stem cell transplantation and MIBG-radionuclide therapy. 
Discussion 
The diagnosis of a neuroblastic tumor in an adult patient is so rare that both clinicians 
and pathologists tend to exclude neuroblastoma from differential diagnosis when the 
patient is an adult. The patient described here had osseous lesions in addition to the  
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mediastinal tumor and the bone marrow infiltration. This was probably – together with 
the positive plasma cell marker VS38c – the reason for the initial false diagnosis of a non-
secretory multiple myeloma. 
The 55-year-old patient showed a poor response to chemotherapy treatment. This is in 
line with previously reported adult or adolescent patients with neuroblastoma, for whom 
the ultimate outcome is generally poor, regardless of the initial disease stage [5, 6]. The 
prognosis of neuroblastoma strongly depends on the age at diagnosis, with significantly 
better survival rates for younger children [1]. Thus, the treatment of neuroblastoma not 
only depends on the disease stage, but also on the patient’s age. Localized tumors in 
children can mostly be cured by surgery only, or sometimes may even be self-limiting. 
However, disseminated tumors in older children require an aggressive multimodality 
approach including surgical resection, radiation therapy and high-dose chemotherapy 
with hematopoietic stem cell rescue. Yet, if treated with the standard protocols used for 
children, even the survival rate for adolescents is low [5]. More aggressive or innovative 
therapeutic approaches are needed for older patients. Ablative chemotherapy followed by 
autologous stem cell transplantation leads to prolonged survival in advanced stage 
diseases [7]. Tandem transplants show some promise with progression-free survival rates 
of over 50% at up to seven years [8]. However, for children older than 18 months with 
disseminated disease, the survival rates remain low at approximately 30%. Therefore, new 
tumor-specific strategies are under investigation. Immunotherapy with antibodies 
targeted at GD2 (a disialoganglioside on the surface of neuroblastoma) produced 
promising preliminary results [9], and may also be labeled with 
131I [10]. The radioisotope 
iodine-131-MIBG in conjunction with hematopoietic stem cell transplantation is effective 
in the treatment of advanced stage disease [11, 12]. Novel approaches in the pursuit for 
MYC-targeting therapies are currently under observation for tumors with NMYC 
amplification, which is one of the clearest indicators of aggressive and chemotherapy-
refractory disease [13]. Knockdown of XAB2, a part of the co-receptor complex that 
inhibits differentiation induction by retinoic acid, enhances the differentiating effect of 
all-trans retinoic acid on resistant neuroblastoma cells [14]. Successful allogeneic stem cell 
transplantation has been reported in a 7-year-old boy with stage IV neuroblastoma [15]. 
However, in addition to survival prolongation, the life quality of the patient is an 
important factor. Due to the rareness of neuroblastomas in adults, the data about their 
prognosis is scarce, but the described cases were mostly diagnosed in advanced stage 
disease and had an unfavorable outcome. The older the patient is at diagnosis, the longer 
and the more indolent the disease course appears to be [5, 6]. As long as remission is not 
an accessible intent, a satisfactory aim may also be disease stabilization, avoiding more 
serious therapeutic side effects. The patient described here had a long disease course with 
few symptoms and retained a good life quality beside the disseminated malignant disease 
for now more than 20 months after the first diagnosis. To properly evaluate the efficacy 
and toxicity of new or more aggressive therapeutic strategies for adolescent and adult 
patients with neuroblastoma, a central collection of the data is necessary.  
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Fig. 1. a Bone marrow smear displaying blast cells. b Histological examination of the bone marrow 
biopsy revealing a profound marrow infiltration with displacement of the hematopoiesis (neuron-
specific enolase staining). 
 
 
 
Fig. 2.  a Diffuse pathological glucose uptake in the bone marrow of the hollow bones and the vertebral 
bodies in the PET and PET-CT scan. b Diffuse iodine-131-MIBG uptake in the bone marrow, including 
the calvarium, as determined by MIBG scintigraphy. 
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